Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation
Subscribe To Our Newsletter & Stay Updated
